Large workforce The company has over 10,000 employees, indicating a sizable client base and broad internal capabilities that can support large-scale pharmaceutical and medical device marketing programs, presenting upsell opportunities for global campaigns and integrated services.

M&A history Historical mergers with INC Research position the firm as a major CRO/communications hybrid with established capabilities in clinical and regulatory communications, suggesting opportunities to cross-sell end-to-end commercialization services and patient engagement solutions.

Healthcare focus Core emphasis on pharmaceutical, biologic, device, and diagnostic commercialization, coupled with patient education and medical policy communications, creates potential for expanded advertising, CME, and public affairs offerings to pharma and biotech clients.

Public market presence Past public listing and high-profile acquisitions imply experience with investor relations and corporate communications for life sciences, making them a potential partner for investor-focused materials, thought leadership campaigns, and FDA/health policy communications.

Revenue scale signals Reported revenue range places the firm in a mid-to-large services tier relative to peers, suggesting opportunities for multi-year managed services contracts, digital transformation in marketing analytics, and expanded digital/social media programs for life sciences brands.